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Objective: Heme oxygenase-1 (Hmox1) is a stress-induced enzyme that catalyzes the degradation of 
heme to carbon monoxide, iron and biliverdin. Induction of Hmox1 and its products protect against 
cardiovascular disease, including ischemic injury. Hmox1 is also a downstream target of the 
transcription factor hypoxia-inducible factor-1α (HIF-1α), a key regulator of the body’s response to 
hypoxia. However, the mechanisms by which Hmox1 confers protection against ischemia-mediated 
injury remain to be fully understood. 
Approach and Results: Hmox1 deficient (Hmox1–/–) mice had impaired blood flow recovery with 
severe tissue necrosis and auto-amputation following unilateral hind limb ischemia. Auto-amputation 
preceded the return of blood flow, and bone marrow transfer from littermate wild-type mice failed to 
prevent tissue injury and auto-amputation. In wild-type mice, ischemia-induced expression of Hmox1 
in skeletal muscle occurred prior to stabilization of HIF-1α. Moreover, HIF-1α stabilization and 
glucose utilization were impaired in Hmox1–/– mice compared with wild-type mice. Experiments 
exposing dermal fibroblasts to hypoxia (1% O2) recapitulated these key findings. Metabolomics 
analyses indicated a failure of Hmox1–/– mice to adapt cellular energy reprogramming in response to 
ischemia. Prolyl-4-hydroxylase inhibition stabilized HIF-1α in Hmox1–/– fibroblasts and ischemic 
skeletal muscle, decreased tissue necrosis and auto-amputation, and restored cellular metabolism to 
that of wild-type mice. Mechanistic studies showed that carbon monoxide stabilized HIF-1α in 
Hmox1–/– fibroblasts in response to hypoxia. 
Conclusion: Our findings suggest that Hmox1 acts both downstream and upstream of HIF-1α, and 
that stabilization of HIF-1α contributes to Hmox1’s protection against ischemic injury independent of 
neovascularization. 
Non-standard abbreviations and acronyms: 





Critical limb ischemia and lower limb amputations represent the end stage of peripheral 
arterial disease (PAD) that affects >200 million patients worldwide.1 Mortality rates for critical limb 
ischemia exceed those of other vascular occlusive diseases and mitigation of classic vascular risk 
factors has not substantially reduced the risk of amputation.2 Moreover, randomized placebo-
controlled trials of gene- and cell-based therapies that primarily target neovascularization have largely 
failed.2 Given that the prevalence of PAD will continue to increase with the aging and growing 
diabetic populations new strategies aimed at prevention and management of critical limb ischemia are 
urgently required. 
 
High plasma concentrations of bilirubin, a product of heme catabolism, are associated with 
protection against PAD and lower limb amputation. The National Health and Nutrition Examination 
Survey (NHANES) reported a 6% reduction in the odds of PAD for every ≈1.7 µmol/L increase in 
serum total bilirubin.3 In the Fenofibrate and Event Lowering in Diabetes (FIELD) study, we reported 
an inverse association of baseline plasma bilirubin and the clinical endpoint of amputation in 9,795 
type 2 diabetic patients.4 Irrespective of placebo or fenofibrate treatment individuals with lower 
bilirubin had increased risk of amputation with a hazard ratio of 1.38 for every 5 µmol/L decrease in 
bilirubin. These studies build upon a body of literature implicating heme catabolism as being 
protective against cardiovascular diseases.5 
 
Heme oxygenase-1 (Hmox1) catalyzes the degradation of heme to carbon monoxide, ferrous 
iron and biliverdin, which is then rapidly reduced to bilirubin by biliverdin reductase. Hmox1 is an 
inducible isoform of heme oxygenase whose transcription is triggered by a wide variety of stressors 
including heme, oxidative stress, UV irradiation and hypoxia. In pre-clinical models, induction of 
Hmox1 represents a crucial response of the cardiovascular system to injury and repair5. For example, 
pharmacological or gene therapy-mediated increase in Hmox1 inhibits vascular smooth muscle cell 
proliferation and intimal hyperplasia,6, 7 promotes endothelial cell growth8 and re-endothelialization,9, 
10 and provides long-term protection against ischemia/reperfusion injury in the heart.11, 12 Similarly, 
Hmox1 gene transfer facilitates blood flow recovery and capillary density in hind limb ischemia,13, 14 
and administration of carbon monoxide15, 16 and bilirubin17 protect against hind limb ischemia-
reperfusion injury. Conversely, Hmox1 deficiency or pharmacological inhibition of its enzymatic 
activity impairs angiogenesis and ischemia-mediated neovascularization in rodent models.13, 14, 18, 19 
 
The adaptive response to ischemia entails a broad program of events that are driven, in part, 
via the transcription factor hypoxia inducible factor-1 (HIF-1). In response to low oxygen tensions the 
transcription factor targets genes involved in angiogenesis, glycolysis, and stress responses, including 
Hmox1.20 However, it is becoming increasingly apparent that Hmox1 itself can exert effects on gene 
transcription7, 21 and downstream energy metabolism21, while carbon monoxide acts as a metabolic 
regulator in cancer cells.22 While multiple lines of evidence support a protective role of Hmox1 against 
vascular ischemia, the mechanisms of protection it affords to the tissue served by the affected vascular 
bed remain unclear. As Hmox1 and HIF-1 are both increased in response to ischemia and associated 
with improved outcomes,14, 18, 23-26 we thought it important to examine their interplay in an attempt to 
better understand how Hmox1 confers protection against ischemia-induced auto-amputation in a 
mouse hind limb model. 
Materials and Methods 
Experimental animals 
All animal experiments were approved by the Garvan/St Vincent’s Animal Ethics Committee 
and performed in accordance with the Australian Code for Care and Use of Animals for Scientific 
Purposes. Hmox1+/– breeding pairs on a BALB/c background were obtained from Dr Soares (Instituto 
de Gulbenkian de Ciencia, Portugal) from a colony originally generated by Dr Yet.27 All mice used in 
these studies were bred at the Victor Chang Cardiac Research Institute BioCORE Facility 
(Darlinghurst, Australia) and the University of Sydney (Camperdown, Australia). Mice were housed in 
cage bedding (PrimeSafe, Australia) on a 12 h light/dark cycle with access to standard chow (rat and 
mouse premium breeder diet 23% protein, Gordons Specialty Feeds, NSW, Australia) and water ad 
 4 
libitum. 
Hind limb ischemia 
Unilateral hind limb ischemia was surgically introduced in ~12-week-old male and female 
homozygous (Hmox1–/–) mice, and sex-matched wild-type (Hmox1+/+) and heterozygous (Hmox1+/–) 
littermates, as described in Online Supplement. Where indicated, mice received 
dimethyloxaloylglycine (DMOG, 8 mg in 250 µL 0.9% saline) or vehicle by intra-peritoneal injection 
immediately prior to surgery then every second day.28 Two observers blinded to genotype and 
treatment scored pedal reflexes and tissue injury as follows: 0, normal; 1, mild discoloration; 2, 
necrosis; 3, auto-amputation below the ankle; 4, auto-amputation above the ankle. The percentage of 
mice with auto-amputation was also determined at each time-point. Pedal reflexes in response to tail 
traction were scored as follows: 0, normal; 1, plantar flexion but not toe flexion; 2, no flexion; 3, 
dragging of the foot; 4, dragging of limb. Blood flow was measured non-invasively using a laser 
Doppler perfusion imager (moorLDI2-HIR, Moor Instruments, UK), as described in Online 
Supplement. 
Bone marrow transplantation 
Bone marrow was isolated from 6-12 weeks-old male Hmox1+/+ or Hmox1–/– donor mice as 
described in Online Supplement. Male mice were used as donors so that their Y chromosome could be 
used to track engraftment and homing to sites of ischemia in female recipient mice.  At 6 weeks of 
age, female Hmox1+/+ or Hmox1–/– mice were irradiated (6.5 Gy) and 1×107 bone marrow donor cells 
administered in 200 μL by tail vein injection using a 25 G needle. After 6 weeks of bone marrow 
engraftment, female recipient mice underwent hind limb ischemia surgery. Donor bone marrow was 
male donor mice  
Histological analyses 
Gastrocnemii were removed, snap-frozen and cryosections (5 μm) obtained, as described in 
Online Supplement. Vessel density was assessed by anti-CD31-phycoerythrin, anti-smooth muscle 
actin-fluorescein isothiocyanate, and anti-laminin antibody, with Alexa Fluor 350. Photomicrographs 
were taken on the Zeiss Axio Imager M1 using the 20× objective (scale bar = 100 μm). Lumen 
diameter and CD31+SMA+ vessels and myocytes were enumerated by blinded observers. SMA+-FITC 
vessels were classified by diameter (<50 µm, 50-100 µm, >100 µm).29 A blinded veterinary 
pathologist (Rothwell Consulting, Sydney, Australia) assessed hind limb cell morphology. Apoptosis 
was assessed in serial sections of gastrocnemius by TUNEL (ApopTag® Peroxidase In Situ Apoptosis 
Detection Kit, Merck-Millipore, S7100) and anti-active caspase-3 antibody staining, as described in 
Online Supplement. Please see the Major Resources Table in the Supplemental Material for antibody 
details. 
High-resolution respirometry 
High-resolution respirometry was performed on red and white muscle fiber types, isolated 
from the medial head of the gastrocnemius, using the Oxygraph O2k system (Oroboros, Innsbruck, 
Austria) as described previously,30 with measurements performed as described in Online Supplement. 
Oxygen concentration was kept above 250 µM with periodic addition of H2O2 (0.1 μM). The 
substrate-uncoupler-inhibition titration protocol was used to determine skeletal muscle respiration, and 
data were analyzed as described previously.30 
Fibroblast isolation and treatment 
Individual fibroblast lines were established from male Hmox1+/+ (n=4) and Hmox1–/– (n=4) 
mice using a skin explant technique,31 with the minor modifications described in Online Supplement. 
Fibroblasts were seeded at a density of 2×104/cm2 and grown in standard tissue culture conditions. 
Culture media (DMEM + 20% FBS) was pre-equilibrated in a H35 Hypoxystation (Don Whitley 
Scientific, UK) at 1% O2, 5% CO2, nitrogen balance, 37 ºC with humidification. Fibroblasts were 
transferred to hypoxia conditions, media replaced with pre-equilibrated media and supplemented with 
500 µM DMOG as indicated for the specified time period. For CORM-A1 studies, 5 µM CORM-A1 
was re-suspended in water or inactivated (iCORM)32. Cells were lysed in sodium dodecyl sulfate 
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(SDS)-urea buffer for protein extraction. 
Glucose uptake 
For ex vivo assays, skeletal muscle glucose uptake was performed in soleus muscle as 
previously described33 with amendments detailed in Online Supplement. Glucose uptake was 
calculated from the intracellular accumulation of [3H]-2-deoxyglucose. For in vitro assays, fibroblasts 
were plated in a 12-well culture plate at 1×105 cells per well in 2 mL DMEM + 10% FBS. Cells were 
then transferred to the hypoxic chamber (1% O2, 5% CO2 at 37 °C humidified) or kept under standard 
tissue culture conditions. Glucose uptake was determined by liquid scintillation counting after 8 h 
incubation of cells with 2-[3H]-deoxy-D-glucose as detailed in Online Supplement. 
Biochemical assays 
For plasma lactate, blood collected by cardiac puncture into lithium-heparin tubes was 
centrifuged at 2,000g for 15 min at 4 °C, and L-lactate assayed in plasma using a fluorimetric assay 
and following the manufacturer’s protocol (Cayman Chemicals, 700510). Pyruvate and lactate were 
determined in cultured fibroblasts (1×106) by a fluorimetric assay following the manufacturer’s 
protocol (Cayman Chemicals, 700470 (pyruvate), 700510 (lactate)). Biliverdin was determined in 
plantaris muscle by LC-MS/MS34 as detailed in Online Supplement. ATP and AMP were determined 
by HPLC-UV35 as detailed in Online Supplement. Metabolic and lipidomic analyses are described in 
the Online Supplement. 
Protein isolation and Western blotting 
Proteins were extracted in SDS-urea buffer and Western blots performed as described in 
Online Supplement using anti-HIF-1α, anti-Hmox1, anti-β-actin, or anti-α-tubulin antibody with anti-
rabbit or anti-mouse horse radish peroxidase as secondary antibody. Lysates from mixed fiber-type 
gastrocnemius tissue were assessed using anti-HIF-1α with anti-mouse IRDye® 800 by LI-COR 
imaging (Odyssey Imager, Licor). X-ray film visualization was used to analyze lysates from cultured 
cells. Densitometry analyses were performed using Image Studio Lite version 5.2.5 (LI-COR 
Biosciences). Ponceau S staining was used for loading control and normalization of data36. Please see 
the Major Resources Table in the Supplemental Material for antibody details. 
RNA isolation and qPCR 
RNA was prepared using TRIzol reagent and qPCR performed using the SensiFast SYBR No-
Rox kit (Bioline) and a LightCycler 480 (Roche), with primer sets detailed in Supplemental Table 1 
and as described in Online Supplement. Hmox1 was normalized to the average of three housekeeping 
genes (Actb, 18s, Hrpt) using the ∆∆CT method.37 
Statistical analysis 
Statistical analysis was performed using GraphPrism version 7 software. Results are expressed 
as mean ± standard error of the mean (SEM). Data was analyzed first for normality (D'Agostino-
Pearson) and equal variance for continuous variables (excepting % survival curves). If passed, 
Student’s t-test, Kruskal-Wallis one-way ANOVA or two-way ANOVA were performed with pos hoc 
tests for between group comparisons where appropriate. For two group comparisons where either test 
failed the Mann-Whitney rank sum test was used. P<0.05 was considered as statistically significant. 
Results 
Hmox1 deficiency is associated with ischemia-induced auto-amputation 
To determine the role of Hmox1 in hind limb ischemia, we utilized Hmox1+/+ and Hmox1–/– 
littermate mice on a BALB/c background, where the oxygen concentration in ischemic tissue more 
closely resembles the value in critical limb ischemia patients with imminent amputation.38, 39 
Compared with C57BL/6, BALB/c mice also possess a lower capacity for compensatory collateral 
artery growth after femoral artery occlusion.39-41 Following induction of unilateral hind limb ischemia, 
Hmox1–/– mice had increased tissue necrosis and auto-amputation as early as 3 days after ischemia, 
and impairment of pedal reflexes compared with Hmox1+/+ mice (Figures 1A-D, Online Figure IA). 
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There were no significant differences in auto-amputation, tissue injury or pedal reflexes between 
Hmox1+/+ mice and Hmox1+/– littermates (Online Figure IB-D). Hematoxylin and eosin staining of 
gastrocnemius tissue 24 h after ischemia displayed features consistent with necrosis (e.g., eosinophilic 
swollen myocytes with loss of nuclei) while apoptosis assessed by TUNEL and active caspase-3 
staining was negligible (Online Figure IE). These data indicate that the Hmox1 allele confers 
protection against ischemia-induced necrosis and auto-amputation. 
 
Non-invasive laser Doppler perfusion monitoring (Figure 1E) demonstrated that blood flow 
recovery was significantly impaired in Hmox1–/– compared with wild-type littermate mice at 17 and 21 
days after ischemia (Figure 1F), i.e., 2 weeks after the onset of auto-amputation. Hmox1 deficiency 
also significantly decreased the density of blood vessels with diameters of 50-100 µm and >100 µm in 
gastrocnemius tissue 21 days after ischemia (Figure 1G), while smaller arterioles were not affected. 
These results confirm a previous study reporting Hmox1 deficiency to attenuate blood flow recovery 
after hind limb ischemia in C57BL/6 mice.14 What is novel, however, is that hind limb ischemia 
caused auto-amputation in Hmox1–/– mice on BALB/c but not C57BL/6 genetic background, and that 
auto-amputation preceded impaired blood flow recovery, suggesting that Hmox1 deficiency in non-
vascular tissue of BALB/c mice contributed to ischemia-induced auto-amputation. 
Bone marrow Hmox1 does not rescue auto-amputation 
To directly assess the contribution of vascular Hmox1 to the auto-amputation phenotype, bone 
marrow transfer experiments were performed. Lethally irradiated female Hmox1–/– and Hmox1+/+ mice 
were reconstituted with male Hmox1+/+ bone marrow cells and, after a period of 6 weeks, unilateral 
hind limb ischemia was introduced. Twenty-one days after hind limb ischemia, bone marrow 
engraftment and migration of progenitors to the site of ischemia was confirmed by PCR detection of 
the sex determining region-Y gene in ischemic plantaris of female recipients (Online Figure IIA). 
Transfer of wild-type bone marrow to Hmox1–/– mice modestly (from 78 to 57%) decreased but did not 
prevent auto-amputation compared with non-irradiated Hmox1–/– mice (compare Figure 2A with 
Figure 1B). Also, wild-type bone marrow transfer failed to significantly improve tissue injury, pedal 
reflexes, neovascularization, and blood perfusion (Figure 2B-E, Online Figure IIB). These results 
indicate that bone marrow Hmox1 and by inference, bone marrow-facilitated neovascularization, was 
not a primary factor responsible for prevention of ischemia-induced tissue necrosis and auto-
amputation in Hmox1+/+ mice, consistent with ischemia-induced auto-amputation preceding blood flow 
recovery in Hmox1–/– mice. 
 
Ischemia-mediated changes in energy metabolism is altered in Hmox1 deficient mice 
We next compared metabolic activity in skeletal muscle of Hmox1+/+ and Hmox1–/– mice 
without (naïve) and with hind limb ischemia. We first determined mitochondrial respiration in red and 
white fibers of the gastrocnemius by high-resolution respirometry.30, 42 In red fibers of naïve Hmox1+/+ 
and Hmox1–/– mice, maximal oxygen flux as well as electron transfer capacity through complex I, 
complex II, and electron transferring flavoprotein, or when oxidative phosphorylation was uncoupled 
were comparable (Figure 3A, B). By comparison, oxygen consumption was negligible in white fibers 
of naïve mice of both genotypes (Online Figure IIIA), consistent with these fibers exhibiting a 
glycolytic phenotype. We next determined ex vivo [3H]-2-deoxyglucose uptake in soleus from naïve 
mice. Naïve Hmox1–/– mice had significantly elevated [3H]-2-deoxyglucose uptake compared with 
Hmox1+/+ littermates (Figure 3C), indicating that Hmox1 deficiency increases glucose demand. 
 
Three days after ischemia, i.e., the time point at which auto-amputation occurred first, 
respiration was essentially undetectable in the ischemic muscle of Hmox1+/+ and Hmox1–/– mice 
(Figure 3D, E). [3H]-2-deoxyglucose uptake was increased in both genotypes, although Hmox1–/– mice 
had a significantly decreased capacity to increase glucose uptake relative to that observed in naïve 
mice (Figure 3F, G). Moreover, plasma lactate was significantly lower in Hmox1–/– compared with 
Hmox1+/+ mice (Figure 3H). Time-course studies revealed a rapid loss in mitochondrial respiration in 
red gastrocnemius fibers of Hmox1+/+ mice as early as 30 min after ischemia, with negligible 
respiration remaining by 3 h (Online Figure IIIC). This was associated with an increase in the tissue 
AMP-to-ATP ratio (Online Figure IIID), indicative of the deteriorating oxidative energy metabolism. 
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In light of this rapid loss of mitochondrial respiration in ischemic tissue, we also examined red fibers 
from the gastrocnemius of the sham-operated, non-ischemic right hind limb 3 days after resection of 
the femoral artery: mitochondrial respiration was repressed in Hmox1–/– compared with Hmox1+/+ mice 
(Figure 3I). This suggested that hind limb ischemia induced a systemic stress and that Hmox1 was 
required to maintain normal mitochondrial respiration under these conditions. In support of this 
notion, Hmox1 expression was induced in the sham-operated right hind limb of ischemic Hmox1+/+ 
compared with naïve Hmox1+/+ mice (Figure 3J). Together, these data indicate that Hmox1 deficiency 
perturbs skeletal glucose uptake and utilization as well as mitochondrial respiration in response to 
ischemia, suggesting that Hmox1 may play a role in ischemia-mediated metabolic reprogramming. 
Ischemia-mediated HIF-1α expression is blunted in Hmox1 deficient mice 
In light of the metabolic perturbations observed in Hmox1–/– mice in response to ischemia, we 
next examined the expression of HIF-1α, as this subunit regulates the heterodimeric transcription 
factor HIF-1 that itself mediates adaptive responses to tissue hypoxia.43 We used a mixed population 
of fibers across the proximal portion of the gastrocnemius, since the expression of HIF-1α44 and 
Hmox145 varies across different skeletal muscle fiber types. As expected, HIF-1α protein expression 
was significantly increased in ischemic skeletal muscle from Hmox1+/+ mice 3 days after ischemia 
(Figure 4A). Strikingly, this response was blunted in Hmox1–/– mice (Figure 4A). At the same time, 
Hmox1 protein was increased in ischemic skeletal muscle of Hmox1+/+ but not Hmox1–/– mice (Figure 
4B), consistent with the presence of a hypoxia response element in the promoter of the Hmox1 gene 
and Hmox1 being a known down-stream target of HIF-1.20 Increased Hmox1 protein expression was 
associated with increased endogenous Hmox activity, as assessed by the increase in skeletal muscle 
content of biliverdin, determined by LC-MS/MS (Figure 4C). 
 
Time-course studies revealed that substantive expression of HIF-1α in ischemic 
gastrocnemius was not observed during the first 16 h of ischemia, i.e., the time period within which 
oxidative energy metabolism becomes blunted, in sharp contrast to the strong induction seen after 72 h 
ischemia (Figure 4A). In contrast to HIF-1α, Hmox1 mRNA and protein increased significantly as 
early as 3 and 6 h after ischemia, respectively in Hmox1+/+ mice (Figure 4B, D). As expected, Hmox1 
mRNA and protein were not detected in skeletal muscle of Hmox1–/– mice before or after ischemia 
(Figure 4D). These data indicate that during the initial 16 h of ischemia, expression of Hmox1 protein 
precedes and is independent of HIF-1α stabilization. 
Hypoxia-induced HIF-1α stabilization and energy metabolism are impaired in Hmox1 deficient 
fibroblasts 
To further explore the relationship between Hmox1, HIF-1α stabilization and energy 
metabolism under low oxygen tensions, we utilized dermal fibroblasts isolated from the dorsum of 
Hmox1–/– and Hmox1+/+ littermate mice. In wild-type fibroblasts, Hmox1 protein expression increased 
time-dependently in response to hypoxia (1% O2), while Hmox1 was not detected in fibroblasts from 
Hmox1–/– mice (Figure 5A). Consistent with the hind limb ischemia data (Figure 4A), Hmox1+/+ 
fibroblasts had significantly increased HIF-1α stabilization in response to hypoxia compared with 
cells from Hmox1–/– mice (Figure 5B). Importantly, hypoxia-mediated induction of Hmox1 protein 
also preceded significant HIF-1α stabilization in wild-type fibroblasts (1 h for Hmox1, Figure 5A; 3 h 
for HIF-1α, Figure 5B). Furthermore, wild-type fibroblasts responded to hypoxia by significantly 
increased uptake of [3H]-2-deoxyglucose (Figure 5C), with associated increases in cellular pyruvate 
and lactate (Figure 5D and E), whereas Hmox1 deficient fibroblasts failed to increase glucose uptake, 
pyruvate and lactate in response to hypoxia. Collectively, these data suggest that Hmox1 induction is 
upstream of, and in part required, for HIF-1α stabilization and metabolic reprogramming in response 
to hypoxia. 
Stabilization of HIF-1α rescues ischemia-induced auto-amputation in Hmox1–/– mice 
We next sought to determine if the observed decrease in HIF-1α stabilization in ischemic 
skeletal muscle could account for the hypoxia-induced auto-amputation in Hmox1–/– mice, making use 
of dimethyloxaloylglycine (DMOG). DMOG is an analog of 2-oxoglutarate that stabilizes HIF-1α by 
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competitively inhibiting prolyl and asparaginyl hydroxylases, and that has been used successfully in a 
variety of animal models.28, 46 DMOG significantly increased HIF-1α in fibroblasts from Hmox1–/– 
mice exposed to normoxia (0 h time point) and hypoxia (Figure 6A). Similar to DMOG, exposure of 
fibroblasts from Hmox1–/– mice to the carbon monoxide-releasing molecule A1 (CORM-A1) but not 
inactivated CORM-A1 (iCORM) significantly increased HIF-1α in response to hypoxia (Figure 6B). 
 
Similar to the situation with isolated fibroblasts, administration of DMOG to Hmox1–/– mice 
resulted in a significant increase in HIF-1α protein in ischemic muscle 3 weeks after ischemia (Figure 
6C). We administered DMOG immediately prior to inducing ischemia, then every other day until 
tissue collection to avoid feedback loops in the HIF-1 pathway.28 Importantly, DMOG significantly 
decreased auto-amputation (Figure 6D) and tissue injury (Figure 6E) in Hmox1–/– mice subjected to 
hind limb ischemia, whereas DMOG had no material effect on blood flow recovery (Figure 6F). 
Preliminary metabolomic and lipidomic analyses of hind limb gastrocnemius muscle of Hmox1+/+ and 
Hmox1–/– mice ± DMOG treatment 5 days after ischemia indicated that Hmox1 deficiency 
significantly increased 1-carbon metabolism and tricarboxylic acid cycle intermediates while tissue 
concentrations of nicotinamide and triglycerides were decreased (Figure 6G, Online Figure IVA, 
Online Supplemental Table II). DMOG treatment reversed these metabolic abnormalities (Figure 6H, 
Online Figure IVB).  
Discussion 
Our study identifies a role for Hmox1 in HIF-1α stabilization in response to hypoxia. We 
show that mice deficient in Hmox1 have impaired HIF-1α stabilization and metabolic abnormalities in 
ischemic skeletal muscle, and that this is associated with auto-amputation of the afflicted limb. 
Pharmacological stabilization of HIF-1α rescues ischemia-induced auto-amputations and tissue 
necrosis, and it normalizes metabolic disturbances in Hmox1–/– mice. In wild-type skeletal muscle and 
isolated fibroblasts, ischemia and hypoxia induce Hmox1 protein prior to HIF-1α stabilization. While 
Hmox1 has been known as a downstream target of HIF-1α, our data suggest a new paradigm for the 
interplay between Hmox1 and this transcription factor, in which Hmox1 contributes to the regulation 
of the response to hypoxia by also acting upstream of HIF-1α. 
 
Hmox1 is induced rapidly in response to a wide variety of stressors and it plays a key role in 
cellular protection.5 The key finding of the current study, i.e., that induction of Hmox1 expression 
preceded HIF-1α stabilization in response to low oxygen tensions and that Hmox1 can work upstream 
of a transcription factor in addition to being its downstream target, is not without precedent. We have 
shown previously that chemically distinct Hmox1 inducers and plasmid-mediated Hmox1 over-
expression increase the Janus-like transcription factor Ying Yang-1 (YY1) in vascular smooth muscle 
cells, and that YY1 itself induces Hmox1.7 Similar to the HIF-1α stabilization reported here, carbon 
monoxide (CO) increased YY1 expression.7 Others reported CO to induce Hmox1 by increasing 
nuclear translocation of the transcription factor Nrf2,47 while hypoxia-mediated nuclear-localization of 
Hmox1 has been shown to activate both Nrf221 and AP148. Thus, our current observations add further 
weight to an emerging body of evidence that implicates Hmox1 in coordinating transcriptional 
responses. 
 
The mechanism by which Hmox1 increases HIF-1α to protect against ischemic injury is the 
subject of future investigations. Increased Hmox1 expression in the ischemic tissue was associated 
with increased heme degradation to biliverdin (Figure 4C) while exogenously added CO, another 
product of heme oxygenase activity, promoted HIF-1α stabilization in fibroblast exposed to hypoxia 
(Figure 6B). These findings suggest that Hmox1 enzymatic activity is required for HIF-1α 
stabilization, although our studies did not test whether the observed increase in HIF-1α stabilization 
was direct or indirect. Otterbein and colleagues reported CO gas (250 ppm) to induce the expression of 
HIF-1α in murine macrophages in vitro and mouse lungs in vivo under normoxic conditions.49 In that 
study, CO was unable to induce HIF-1α expression in mitochondria-deficient macrophages, and 
hydrogen peroxide (H2O2) alone increased HIF-1α expression while the inclusion of the H2O2-
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metabolizing enzyme catalase attenuated the ability of CO to increase HIF-1α.49 The implied role of 
mitochondria-derived H2O2 in promoting HIF-1α expression by CO is supported by the observation 
that mitochondrial H2O2 increases as a result of CO binding to cytochrome aa3,50 although this non-
canonical mechanism of HIF-1α stabilization remains controversial51 just as the molecular details of 
how mitochondrial H2O2 increases HIF-1α remain obscure. As an alternative mechanism, CO could 
inhibit HIF-1α ubiquitination by enhancing its interaction with the chaperone, heat shock protein-90.52 
Irrespective of the underlying mechanism, it is known is that administration of exogenous CO protects 
rat16 and mouse15 hind limb muscle from ischemia-reperfusion injury, and the data presented here 
suggest that this may extend to endogenous CO, produced by Hmox1 in the ischemic muscle. 
 
HIF-1 initiates a broad set of transcription programs coordinating neovascularization, 
glycolysis and stress responses. Consistent with this, DMOG was reported to increase vessel density in 
the hind limb of C57BL/6 mice, and this was associated with HIF-1α stabilization.28 Also, combined 
gene therapies of Hmox1 and HIF-1α improved neovascularization and limb salvage following 
ischemia in wild-type C57BL/6 mice over single therapy.26 Similarly, combined Hmox1 and Vegfa 
gene therapy decreased the incidence of necrotic toes in wild-type14 and Hmox1–/–53 C57BL/6 mice, 
while pharmacological inhibition of Hmox1 impaired blood flow recovery and increased limb necrosis 
in C57BL/6 mice18 and mice heterozygous for the HIF-1α null allele have decreased blood flow 
recovery and limb salvage following ischemia.23 By comparison, using mice exclusively on a BALB/c 
strain background we observed modest improvements in ischemia-mediated neovascularization and 
blood flow recovery in Hmox1–/– animals whether they were reconstituted with wild-type bone marrow 
or treated with DMOG. The BALB/c strain background is well known to have increased tissue 
necrosis, and diminished Vegfa expression and collateral networks in response to ischemia40, 54 when 
compared to the C57BL/6 strain. Indeed, we did not detect significant induction of Vegfa in either 
Hmox1+/+ or Hmox1–/– mice in response to ischemia (not shown). Our observations suggest that 
increasing Hmox1 can protect against ischemic injury via the HIF-1α pathway independent of 
substantial improvement of neovascularization. 
 
Given the divergence between neovascularization and tissue necrosis in the present 
investigation, we examined the role of Hmox1 in HIF-1α mediated glucose utilization. Notably, we 
found that impaired HIF-1α stabilization in Hmox1–/– mice was associated with diminished capacity of 
the skeletal muscle to increase glucose uptake and its utilization in response to ischemia. These 
observations were echoed in isolated fibroblasts. We further observed ischemic injury to elicit a 
remote response in the contralateral limb of Hmox1–/–￼￼ by modulating cellular energy metabolism. 
 
Current management and treatment approaches for PAD have not led to a substantial reduction 
in the risk of amputation over the past 30 years.18 Moreover, larger randomized placebo-controlled 
trials of angiogenic gene-orientated and cell-based therapies have failed to translate promising pre-
clinical targets.2 This suggests that promoting neovascularization alone is insufficient to prevent the 
sequelae and consequence of limb ischemia, specifically amputation. In the present study, we 
observed skeletal muscle biliverdin IXα concentrations to significantly increase in Hmox1+/+ but not 
Hmox1–/– mice after three days of ischemia, a time point that coincided with the onset of auto-
amputations. As the biliverdin IXα detected in Hmox1–/– mice could only come from constitutively 
active Hmox2, our findings also imply that Hmox2 alone is not sufficient to prevent auto-amputations. 
It is important to note that tissue biliverdin is the direct product of Hmox activity while plasma 
bilirubin is only a surrogate. Nevertheless, our mouse study recapitulates the key observation reported 
in the FIELD study, namely an inverse association between plasma bilirubin concentrations and lower 
limb amputation.4 What remains to be determined is whether bilirubin, a potent antioxidant itself 
conveys the protection against auto-amputations observed in this study. At the least, it is a potential 
biomarker for risk of non-traumatic lower limb amputations in type 2 diabetes. 
 
While our data indicate a novel relationship between Hmox1 and HIF-1α in protecting against 
ischemia-induced auto-amputations, species- and tissue-specific effects should be considered. In 
mouse and rat cells it has been shown consistently that hypoxia induces HIF-1α, which can activate 
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the hypoxia response element within the Hmox1 promoter. Conversely, in human cells the response is 
varied, with hypoxia increasing HMOX1 expression in dermal fibroblasts but failing to do so in 
multiple endothelial cell types.56 These observations may be explained, in part, by the presence or 
relative absence of Bach1, a hypoxia-induced repressor of HMOX1 transcription.57 In the current study 
we utilized DMOG as a proof-of-principle tool to enhance HIF-1α stability in skeletal muscle and 
prevent auto-amputations in Hmox1–/– mice. DMOG normalized several metabolic abnormalities 
observed in the ischemic skeletal muscle of Hmox1–/– mice. Of the latter, the decrease in serine and 
methionine in Hmox1 deficiency provides separate evidence for Hmox1 being upstream of HIF-1α, as 
HIF-1α activates the serine/1-carbon metabolism pathway.58 Also, HIF-1α inhibits the TCA cycle59 
and fatty acid β-oxidation,60 so that a comparatively more active TCA cycle and β-oxidation in 
Hmox1–/– than WT mice could explain the observed increase and decrease in TCA intermediates and 
triglycerides, respectively. As hypoxia decreases NAD+,61 the finding that Hmox1 deficiency further 
decreases nicotinamide is consistent with Hmox1–/– mice already experiencing an element of hypoxic 
stress. While we did not examine the effect of DMOG on HIF-1α stability in the endothelium, neurons 
and circulating inflammatory cells, previous studies confirmed the broad specificity of DMOG46, 62, 63 
Thus, our current study does not specifically delineate the role of skeletal muscle HIF-1α in protecting 
against auto-amputation in the absence of Hmox1. 
 
In summary, we report a novel role for skeletal muscle Hmox1 in which it stabilizes HIF-1α 
and promotes effective glucose utilization to limit ischemia-induced tissue necrosis and auto-
amputations. Moreover, pharmacological stabilization of HIF-1α in Hmox1 deficiency limits 
ischemia-induced tissue necrosis and prevents auto-amputations. Insights obtained from our current 
study may have important implications for critical limb ischemia, cardiovascular disease in general, 
and other pathologies in which oxygen supply and energy metabolism are perturbed. 
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Highlights 
• Heme oxygenase-1 (Hmox1) deficiency promotes auto-amputation following hind limb ischemia 
• Heme oxygenase-1 stabilizes hypoxia-inducible factor-1α (HIF-1α) 
• Stabilization of HIF-1α rescues ischemia-induced auto-amputation in Hmox1 deficiency 
• Carbon monoxide, the product of Hmox1 enzymatic activity, stabilizes HIF-1α 
Figure Legends 
Figure 1. Hmox1 deficiency is associated with ischemia–induced auto-amputation and impaired 
blood flow recovery. Unilateral hind limb ischemia was surgically induced in male and female 
Hmox1+/+ and Hmox1–/– mice, with sham preparation of the contralateral limb. (A) Representative 
photographs of sham-operated (S) and ischemic (I) hind limbs. (B) Incidence of auto-amputation. (C) 
Tissue injury score: 0, normal; 1, mild discoloration; 2, necrosis; 3, auto-amputation below the ankle; 4, 
auto-amputation above the ankle. (D) Pedal reflex score: 0, normal; 1, plantar but not toe flexion; 2, no 
flexion; 3, dragging of foot; 4, dragging of limb. (E) Representative laser Doppler perfusion images 
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with red pixels indicating maximal perfusion. (F) Laser Doppler blood perfusion ratio in the ischemic 
versus non-ischemic hind limb. (G) Vessel density per myocyte grouped by lumen diameter (<50 µm, 
50-100 µm, >100 µm) in gastrocnemius tissue. Data were enumerated by blinded observers and are 
expressed as mean ± SEM, n=10 per genotype. Results in (B)-(D) and (F) were assessed by 2-way 
ANOVA with repeated measures in (C)-(D) by Sidak’s multiple comparison test, and in (G) by Mann-
Whitney test, *P<0.05. 
Figure 2. Hmox1 in bone marrow cells does not fully rescue auto-amputations in response to 
ischemia. Bone marrow transfer experiments were performed between male Hmox1+/+ donors and 
irradiated female Hmox1+/+ or Hmox1–/– recipients. At 42 d post-transfer, unilateral hind limb ischemia 
was surgically induced with sham preparation of the contralateral limb. (A) Incidence of auto-
amputation. (B) Tissue injury score: 0, normal; 1, mild discoloration; 2, necrosis; 3, auto-amputation 
below the ankle; 4, auto-amputation above the ankle. (C) Pedal reflex score: 0, normal; 1, plantar but 
not toe flexion; 2, no flexion; 3, dragging of foot; and 4, dragging of limb. (D) Laser Doppler blood 
perfusion ratio in the ischemic versus non-ischemic hind limb. (E) Vessel density per myocyte grouped 
by lumen diameter (<50 µm, 50-100 µm, >100 µm) in gastrocnemius tissue. Data were enumerated by 
blinded observers and are expressed as mean ± SEM, n=6-7 per genotype. Results in (A)-(D) were 
assessed by 2-way ANOVA with repeated measures in (B)-(D) by Sidak’s multiple comparison test, 
and in (E) by Mann-Whitney test, *P<0.05. 
Figure 3. Hmox1 affects energy metabolism and glucose utilization in response to ischemia. 
Unilateral hind limb ischemia was surgically induced in male and female Hmox1+/+ and Hmox1–/– mice 
with sham preparation of the contralateral limb as indicated. (A) Maximal oxidative phosphorylation 
(PMAX), and (B) electron transfer capacity through complex I (PCI), complex II (PCII), electron 
transferring flavoprotein (PETF) and uncoupled oxidative phosphorylation (ETS) in red naïve muscle 
fibers of gastrocnemius determined by high-resolution respirometry in naïve mice. (C) Glucose 
utilization in soleus of naïve mice as determined by ex vivo [3H]-2-deoxyglucose uptake. (D) Maximal 
oxidative phosphorylation (PMAX), and (E) electron transfer capacity through complex I (PCI), complex 
II (PCII), electron transferring flavoprotein (PETF) and uncoupled oxidative phosphorylation (ETS) in red 
ischemic muscle fibers of gastrocnemius determined by high-resolution respirometry 3 days post 
ischemia. (F) Glucose utilization in soleus of ischemic mice 3 days after ischemia as determined by ex 
vivo [3H]-2-deoxyglucose uptake. Glucose utilization (G), plasma lactate (H) and maximal oxidative 
phosphorylation (PMAX) in red sham-operated muscle fibers of gastrocnemius (I) in ischemic mice with 
data in (G)-(H) expressed as a fold change of naïve mice. (J) Hmox1 protein expression in red sham-
operated muscle of gastrocnemius. Data are expressed as mean ± SEM, n=3-12 mice per genotype. 
Results in (C) assessed by unpaired t-test, (G)-(H) assessed by 2-way ANOVA, (I) assessed by Mann-
Whitney test, *P<0.05 compared to naïve Hmox1+/+ mice. 
Figure 4. Hmox1 stabilizes HIF-1α in response to ischemia. Unilateral hind limb ischemia was 
surgically induced in male and female Hmox1+/+ and Hmox1–/– mice and the ischemic tissues assessed 
by Western blot for (A) HIF-1α and Hmox1 (B) using gastrocnemius. Ctrl refers to DMOG-treated 
muscle (A) and hemin-treated mouse endothelial cells (B). (C) Concentration of biliverdin in tibialis 
anterior determined by LC-MS/MS. (D) qPCR analysis of Hmox1 mRNA in plantaris. Data are 
expressed as mean ± SEM, n=3-6 mice per genotype and were assessed by 2-way ANOVA, *P<0.05 
compared to naïve (0 h time point) Hmox1+/+ mice. 
Figure 5. Hmox1 stabilizes HIF-1α and is required for the metabolic response to hypoxia in vitro. 
Dermal fibroblasts cultured from Hmox1+/+ and Hmox1–/– mice were exposed to 1% O2 as indicated. 
Western blot analysis of (A) Hmox1 and (B) HIF-1 α. (C) [3H]-2-deoxyglucose uptake. Intracellular 
pyruvate (D) and lactate (E). Western blots in (A)-(B) are representative of at least 3 fibroblast lines 
derived independently per genotype. Data are expressed as mean ± SEM and were analyzed by 2-way 
ANOVA, *P<0.05, compared to Hmox1+/+ normoxia (0 h time point; air). 
Figure 6. DMOG improves HIF-1α stabilization in response to hypoxia in Hmox1 deficiency. 
Dermal fibroblasts were cultured from Hmox1–/– mice. (A) Fibroblasts were treated with media control 
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or 500 µM DMOG, exposed to 1% O2 for the time indicated, followed by Western blot analysis of HIF-
1α. Data are expressed as mean ± SEM, n=3 and assessed by 2-way ANOVA, *P<0.05. (B) Fibroblasts 
were treated with media control or 500 µM DMOG, 5.8 µM CORM-A1 or iCORM-A1, exposed to 1% 
O2 for 30 min, followed by Western blot analysis of HIF-1α. Data are expressed as mean ± SEM, n=7 
and were assessed by 1-tailed Mann-Whitney test, *P<0.05, compared to 1% O2 control. Unilateral hind 
limb ischemia was surgically induced in Hmox1–/– and wild-type littermate mice of both sexes. DMOG 
(8 mg/mouse; or saline control (Ctrl)) was administered by i.p. injection before surgery then every other 
day. (C) Western blot analysis of HIF-1α in gastrocnemius. (D) Incidence of auto-amputation. (E) 
Tissue injury score: 0, normal; 1, mild discoloration; 2, necrosis; 3, auto-amputation below the ankle; 4, 
auto-amputation above the ankle. (F) Laser Doppler blood perfusion ratio in the ischemic versus non-
ischemic hind limb. Metabolic pathways of metabolites detected using targeted analysis and 
significantly altered in (G) Hmox1–/– mice treated with saline (n=2) compared to Hmox1–/– mice treated 
with DMOG (n=4), and (H) Hmox1–/– mice treated with saline compared to wild-type mice (n=6). 1CM, 
1-carbon metabolism; TCA, tricarboxylic acid cycle; TAG, triglycerides. Data were enumerated by 
blinded observers and are expressed as mean ± SEM, n=12 per genotype. Results were assessed by 
Mann-Whitney test in (C), and (D)-(F) by 2-way ANOVA with repeated measures in (E)-(F) by Sidak’s 
multiple comparison test, *P<0.05. 
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